Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • M&A / Deals
  • Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling
  • M&A / Deals

Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling

BioSpace

A trifecta of newly inked tech partnerships--from Eli Lilly, Bristol Myers Squibb and Incyte--exemplify the increasingly central role that AI is playing in drug development.

Read full story

pharminent May 21, 2026 (Last updated: May 21, 2026)

BioSpace

A trifecta of newly inked tech partnerships–from Eli Lilly, Bristol Myers Squibb and Incyte–exemplify the increasingly central role that AI is playing in drug development.

Read full story

Post navigation

Previous: BioMarin bounces back as Voxzogo performs ‘bigger than expected’ in new indication
Next: Lilly’s ‘triple G’ retatrutide aces crucial obesity trial

Related Stories

  • M&A / Deals

Solstice Oncology secures $225m to drive porustobart’s development for cancer

pharminent September 10, 2026
  • M&A / Deals

UK’s Claret Capital raises 575m for European biotechs

pharminent September 7, 2026
  • M&A / Deals

GSK wagers up to $1.3B on a different kind of cancer drug

pharminent September 3, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.